Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of TAK-438 vs AG-1749 for prevention of NSAID-associated peptic ulcer recurrence
jRCT2080221571Phase 3
- Sponsor
- Takeda
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of vonoprazan in gastric ulcer, duodenal ulcer and Peptic ulcer disease (PUD) (2 arms), sponsored by Takeda. Primary endpoints: Long-term safety of TAK-438 compared with AG-1749 and Efficacy in preventing recurrent gastric or duodenal ulcers.
02
Drugs
vonoprazan
03
Conditions
gastric ulcerduodenal ulcerPeptic ulcer disease (PUD)
Beyond the preview
Go deeper on jRCT2080221571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221571.